1566 related articles for article (PubMed ID: 34739716)
21. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario.
Nasreen S; Chung H; He S; Brown KA; Gubbay JB; Buchan SA; Fell DB; Austin PC; Schwartz KL; Sundaram ME; Calzavara A; Chen B; Tadrous M; Wilson K; Wilson SE; Kwong JC;
Nat Microbiol; 2022 Mar; 7(3):379-385. PubMed ID: 35132198
[TBL] [Abstract][Full Text] [Related]
22. Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know.
Rasmussen SA; Kelley CF; Horton JP; Jamieson DJ
Obstet Gynecol; 2021 Mar; 137(3):408-414. PubMed ID: 33370015
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 vaccines for cancer patients: a call to action.
Corti C; Crimini E; Tarantino P; Pravettoni G; Eggermont AMM; Delaloge S; Curigliano G
Eur J Cancer; 2021 May; 148():316-327. PubMed ID: 33770576
[TBL] [Abstract][Full Text] [Related]
24. Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.
Nguyen TT; Quach THT; Tran TM; Phuoc HN; Nguyen HT; Vo TK; Vo GV
Biomed Pharmacother; 2022 Mar; 147():112650. PubMed ID: 35066301
[TBL] [Abstract][Full Text] [Related]
25. COVID vaccination can be performed in patients with a history of allergic reactions to the vaccines or their components: experience from a specialist clinic in South Australia.
Tunbridge M; Perkins G; Lee M; Salehi T; Ryoo D; Kette F; Smith W; Gold M; Le TA; Yuson C; Hissaria P
Intern Med J; 2022 Nov; 52(11):1884-1890. PubMed ID: 35848521
[TBL] [Abstract][Full Text] [Related]
26. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
[TBL] [Abstract][Full Text] [Related]
27. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies.
Di Fusco M; Lin J; Vaghela S; Lingohr-Smith M; Nguyen JL; Scassellati Sforzolini T; Judy J; Cane A; Moran MM
Expert Rev Vaccines; 2022 Apr; 21(4):435-451. PubMed ID: 35112973
[TBL] [Abstract][Full Text] [Related]
28. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
[TBL] [Abstract][Full Text] [Related]
29. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
[TBL] [Abstract][Full Text] [Related]
30. Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease.
Algaba A; Romero S; Granja A; Garza D; Aller M; Barrero S; Guerra I; Gil M; Pizarro N; Ruiz P; Prieto S; Hernández B; Pou A; Bermejo F
Gastroenterol Hepatol; 2023 Jan; 46(1):48-53. PubMed ID: 35605819
[TBL] [Abstract][Full Text] [Related]
31. Recent review of COVID-19 management: diagnosis, treatment and vaccination.
Chavda VP; Vuppu S; Mishra T; Kamaraj S; Patel AB; Sharma N; Chen ZS
Pharmacol Rep; 2022 Dec; 74(6):1120-1148. PubMed ID: 36214969
[TBL] [Abstract][Full Text] [Related]
32. Clinical Course of 53 Previously Vaccinated Patients Admitted to the National Hospital in Warsaw, Poland with COVID-19 Between November 2021 and March 2022.
Zaczyński A; Hampel M; Piątkiewicz P; Nasiłowski J; Butkiewicz S; Religioni U; Barańska A; Malm M; Neumann-Podczaska A; Vaillancourt R; Merks P
Med Sci Monit; 2023 Apr; 29():e939841. PubMed ID: 37118889
[TBL] [Abstract][Full Text] [Related]
33. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
34. Does COVID-19 Vaccination Warrant the Classical Principle "
Doulberis M; Papaefthymiou A; Kotronis G; Gialamprinou D; Soteriades ES; Kyriakopoulos A; Chatzimichael E; Kafafyllidou K; Liatsos C; Chatzistefanou I; Anagnostis P; Semenin V; Ntona S; Gkolia I; Papazoglou DD; Tsinonis N; Papamichos S; Kirbas H; Zikos P; Niafas D; Kountouras J
Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33803295
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, Spain.
Mallah N; Pardo-Seco J; Ares-Gómez S; López-Pérez LR; González-Pérez JM; Rosón B; Otero-Barrós MT; Durán-Parrondo C; Nartallo-Penas V; Mirás-Carballal S; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Gómez-Carballa A; Salas A; Martinón-Torres F
Pediatr Allergy Immunol; 2023 Oct; 34(10):e14037. PubMed ID: 37877845
[TBL] [Abstract][Full Text] [Related]
36. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
37. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Maternal and Neonatal Antibody Levels After COVID-19 Vaccination vs SARS-CoV-2 Infection.
Flannery DD; Gouma S; Dhudasia MB; Mukhopadhyay S; Pfeifer MR; Woodford EC; Briker SM; Triebwasser JE; Gerber JS; Morris JS; Weirick ME; McAllister CM; Hensley SE; Puopolo KM
JAMA Netw Open; 2022 Nov; 5(11):e2240993. PubMed ID: 36350652
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).
Gauci ML; Coutzac C; Houot R; Marabelle A; Lebbé C;
Eur J Cancer; 2021 May; 148():121-123. PubMed ID: 33743480
[No Abstract] [Full Text] [Related]
40. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
